SK2302003A3 - Pharmaceutical formulation of salmeterol and fluticasone propionate - Google Patents

Pharmaceutical formulation of salmeterol and fluticasone propionate Download PDF

Info

Publication number: SK2302003A3
Authority: SK; Slovakia
Prior art keywords: salmeterol; fluticasone propionate; physiologically acceptable; acceptable salt; treatment
Prior art date: 2000-08-31

Application number

SK230-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Donald Herbert Hortsman

Claire Julia Maden

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-31

Filing date

2001-08-31

Publication date

2003-08-05

2001-08-31 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2003-08-05 Publication of SK2302003A3 publication Critical patent/SK2302003A3/sk

Links

WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 title claims abstract description 30
239000008194 pharmaceutical composition Substances 0.000 title claims description 11
229940021597 salmeterol and fluticasone Drugs 0.000 title abstract description 5
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 24
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 28
229960004017 salmeterol Drugs 0.000 claims description 28
229960000289 fluticasone propionate Drugs 0.000 claims description 25
150000003839 salts Chemical class 0.000 claims description 24
229950000339 xinafoate Drugs 0.000 claims description 14
239000003814 drug Substances 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 3
229940124597 therapeutic agent Drugs 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
239000000203 mixture Substances 0.000 description 14
238000009472 formulation Methods 0.000 description 6
208000000059 Dyspnea Diseases 0.000 description 5
206010013975 Dyspnoeas Diseases 0.000 description 5
230000006872 improvement Effects 0.000 description 5
239000000443 aerosol Substances 0.000 description 4
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 4
208000006673 asthma Diseases 0.000 description 4
230000008859 change Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
229940124624 oral corticosteroid Drugs 0.000 description 4
239000000902 placebo Substances 0.000 description 4
229940068196 placebo Drugs 0.000 description 4
239000000843 powder Substances 0.000 description 4
230000000241 respiratory effect Effects 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000005713 exacerbation Effects 0.000 description 3
230000036541 health Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 2
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000003862 health status Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000004199 lung function Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
239000003380 propellant Substances 0.000 description 2
229960002052 salbutamol Drugs 0.000 description 2
208000013220 shortness of breath Diseases 0.000 description 2
239000007921 spray Substances 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229940070384 ventolin Drugs 0.000 description 2
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 1
208000000884 Airway Obstruction Diseases 0.000 description 1
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241000950638 Symphysodon discus Species 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000013066 combination product Substances 0.000 description 1
229940127555 combination product Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960000265 cromoglicic acid Drugs 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940112141 dry powder inhaler Drugs 0.000 description 1
239000000428 dust Substances 0.000 description 1
-1 e.g. theophylline Chemical compound 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229960002714 fluticasone Drugs 0.000 description 1
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
229940125369 inhaled corticosteroids Drugs 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
229960001888 ipratropium Drugs 0.000 description 1
HOQADATXFBOEGG-UHFFFAOYSA-N isofenphos Chemical compound CCOP(=S)(NC(C)C)OC1=CC=CC=C1C(=O)OC(C)C HOQADATXFBOEGG-UHFFFAOYSA-N 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000003595 mist Substances 0.000 description 1
NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
229960000797 oxitropium Drugs 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
229940127211 short-acting beta 2 agonist Drugs 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
229940110309 tiotropium Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Otolaryngology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Treatment Of Water By Ion Exchange (AREA)

SK230-2003A 2000-08-31 2001-08-31 Pharmaceutical formulation of salmeterol and fluticasone propionate SK2302003A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US22938100P	2000-08-31	2000-08-31
PCT/GB2001/003928 WO2002017894A2 (fr)	2000-08-31	2001-08-31	Utilisation d'une combinaison de salmeterol et de propionate de fluticasone

Publications (1)

Publication Number	Publication Date
SK2302003A3 true SK2302003A3 (en)	2003-08-05

Family

ID=22860986

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK230-2003A SK2302003A3 (en)	2000-08-31	2001-08-31	Pharmaceutical formulation of salmeterol and fluticasone propionate

Country Status (24)

Country	Link
US (1)	US20040009963A1 (fr)
EP (1)	EP1313484A2 (fr)
JP (1)	JP2004507494A (fr)
KR (1)	KR20030031997A (fr)
CN (1)	CN1449288A (fr)
AP (1)	AP2003002753A0 (fr)
AR (1)	AR030516A1 (fr)
AU (1)	AU2001284236A1 (fr)
BG (1)	BG107596A (fr)
BR (1)	BR0113555A (fr)
CA (1)	CA2420532A1 (fr)
EA (1)	EA200300152A1 (fr)
EC (1)	ECSP034487A (fr)
HU (1)	HUP0303755A2 (fr)
IL (1)	IL154403A0 (fr)
MA (1)	MA25834A1 (fr)
MX (1)	MXPA03001752A (fr)
NO (1)	NO20030899L (fr)
OA (1)	OA12370A (fr)
PE (1)	PE20020387A1 (fr)
PL (1)	PL365582A1 (fr)
SK (1)	SK2302003A3 (fr)
WO (1)	WO2002017894A2 (fr)
ZA (1)	ZA200301475B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0106031D0 (en) *	2001-03-12	2001-05-02	Glaxo Group Ltd	Use
WO2004028545A1 (fr) *	2002-09-25	2004-04-08	Astrazeneca Ab	Combinaison d'un agoniste $g(b)2 a action prolongee et d'un glucocorticosteroide dans le traitement de maladies fibrotiques
AU2003254429A1 (en) *	2003-08-06	2005-02-25	Galephar M/F	Advantageous combinations for inhalation of nacystelyn and bronchodilators
TR200907913A2 (tr) *	2009-10-20	2011-05-23	Bi̇lgi̇ç Mahmut	İnhalason yolu ile alınmak üzere kuru toz formunda farmasötik bileşim
US8834931B2 (en)	2009-12-25	2014-09-16	Mahmut Bilgic	Dry powder formulation containing tiotropium for inhalation
TR201000681A2 (tr) *	2010-01-29	2011-08-22	B�Lg�� Mahmut	İnhalasyon yoluyla alınan kuru toz formülasyonları.
TR200909791A2 (tr) *	2009-12-25	2011-07-21	B�Lg�� Mahmut	Salmeterol ve flutikazon içeren farmasötik bileşim@
WO2014007772A2 (fr)	2012-07-05	2014-01-09	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Compositions d'inhalation contenant du glucose anhydre
US20150224197A1 (en) *	2012-07-05	2015-08-13	Arven Ilac Sanayi Ve Ticaret A.S.	Inhalation compositions
US10105316B2 (en)	2012-07-05	2018-10-23	Arven llac Sanayi Ve Ticaret A.S.	Inhalation compositions comprising muscarinic receptor antagonist
AU2014261538A1 (en) *	2013-04-29	2015-12-10	Sanofi Sa	Inhalable pharmaceutical compositions and the inhaler devices containing them
MA41378A (fr) *	2015-01-20	2017-11-28	Teva Branded Pharmaceutical Prod R & D Inc	Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
GB202202297D0 (en)	2022-02-21	2022-04-06	Verona Pharma Plc	Formulation production process
EP4568677A1 (fr) *	2022-08-08	2025-06-18	Verona Pharma PLC	Ensifentrine (rpl-554) pour augmentation de la fonction pulmonaire
CN121620356A (zh)	2023-06-26	2026-03-06	维罗纳制药公司	包含恩塞芬汀的颗粒组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL104068A (en) *	1991-12-12	1998-10-30	Glaxo Group Ltd	Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9808802D0 (en) *	1998-04-24	1998-06-24	Glaxo Group Ltd	Pharmaceutical formulations
GB9924992D0 (en) *	1999-10-21	1999-12-22	Glaxo Group Ltd	Pharmaceutical aerosol formulations
EP1248597B1 (fr) *	1999-12-24	2005-03-30	Glaxo Group Limited	Formulation pharmaceutique en aerosol de salmeterol et de propionate de fluticasone

2001
- 2001-08-29 PE PE2001000867A patent/PE20020387A1/es not_active Application Discontinuation
- 2001-08-29 AR ARP010104122A patent/AR030516A1/es unknown
- 2001-08-31 KR KR10-2003-7002890A patent/KR20030031997A/ko not_active Withdrawn
- 2001-08-31 EP EP01963205A patent/EP1313484A2/fr not_active Withdrawn
- 2001-08-31 AP APAP/P/2003/002753A patent/AP2003002753A0/en unknown
- 2001-08-31 CA CA002420532A patent/CA2420532A1/fr not_active Abandoned
- 2001-08-31 JP JP2002522868A patent/JP2004507494A/ja active Pending
- 2001-08-31 IL IL15440301A patent/IL154403A0/xx unknown
- 2001-08-31 AU AU2001284236A patent/AU2001284236A1/en not_active Abandoned
- 2001-08-31 MX MXPA03001752A patent/MXPA03001752A/es unknown
- 2001-08-31 EA EA200300152A patent/EA200300152A1/ru unknown
- 2001-08-31 WO PCT/GB2001/003928 patent/WO2002017894A2/fr not_active Ceased
- 2001-08-31 PL PL01365582A patent/PL365582A1/xx not_active Application Discontinuation
- 2001-08-31 HU HU0303755A patent/HUP0303755A2/hu unknown
- 2001-08-31 CN CN01814708A patent/CN1449288A/zh active Pending
- 2001-08-31 OA OA1200300054A patent/OA12370A/en unknown
- 2001-08-31 SK SK230-2003A patent/SK2302003A3/sk unknown
- 2001-08-31 US US10/363,438 patent/US20040009963A1/en not_active Abandoned
- 2001-08-31 BR BR0113555-4A patent/BR0113555A/pt not_active Application Discontinuation
2003
- 2003-02-20 EC EC2003004487A patent/ECSP034487A/es unknown
- 2003-02-24 ZA ZA200301475A patent/ZA200301475B/en unknown
- 2003-02-26 NO NO20030899A patent/NO20030899L/no not_active Application Discontinuation
- 2003-02-27 MA MA27058A patent/MA25834A1/fr unknown
- 2003-02-27 BG BG107596A patent/BG107596A/bg unknown

Also Published As

Publication number	Publication date
HUP0303755A2 (hu)	2004-04-28
PE20020387A1 (es)	2002-06-24
MXPA03001752A (es)	2003-06-04
KR20030031997A (ko)	2003-04-23
ZA200301475B (en)	2004-05-24
AR030516A1 (es)	2003-08-20
OA12370A (en)	2004-03-19
WO2002017894A2 (fr)	2002-03-07
ECSP034487A (es)	2003-03-31
NO20030899D0 (no)	2003-02-26
NO20030899L (no)	2003-04-28
MA25834A1 (fr)	2003-07-01
BR0113555A (pt)	2003-07-22
EP1313484A2 (fr)	2003-05-28
CN1449288A (zh)	2003-10-15
JP2004507494A (ja)	2004-03-11
AU2001284236A1 (en)	2002-03-13
IL154403A0 (en)	2003-09-17
PL365582A1 (en)	2005-01-10
EA200300152A1 (ru)	2003-08-28
AP2003002753A0 (en)	2003-06-30
US20040009963A1 (en)	2004-01-15
BG107596A (bg)	2004-01-30
CA2420532A1 (fr)	2002-03-07
WO2002017894A3 (fr)	2002-08-08

Publication	Publication Date	Title
US9446054B2 (en)	2016-09-20	Pharmaceutical products and composition comprising specific anticholinergic agents, β-2 agonists and corticosteroids
KR100234864B1 (ko)	1999-12-15	기도 및 폐질환을 치료하기 위한 모메타손푸로에이트 약제
US20030119859A1 (en)	2003-06-26	Medical combinations comprising tiotropium and rofleponide
US20030113269A1 (en)	2003-06-19	Medical combinations comprising tiotropium and fluticasone proprionate
RS20050615A (sr)	2007-09-21	Lek koji sadrži visoko potentni dugotrajni beta2-agonist u kombinaciji sa drugim aktivnim sastojcima
US20140113888A1 (en)	2014-04-24	Novel Combination of Therapeutic Agents
US20050042171A1 (en)	2005-02-24	Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma
US20040009963A1 (en)	2004-01-15	Use of salmeterol and fluticasone propionate combination
US9795561B2 (en)	2017-10-24	Combination of umeclidinium, fluticasone propionate and salmeterol xinafoate for use in the treatment of inflammatory or respiratory tract diseases
US20030114537A1 (en)	2003-06-19	Medical combinations comprising mometasone and salmeterol
WO2001078742A1 (fr)	2001-10-25	Combinaison medicale comprenant du salmeterol et du budesonide
JP2014237666A (ja)	2014-12-18	アルホルモテロール及びチオトロピウムの組成物及びその使用方法
US20110200647A1 (en)	2011-08-18	Pulmonary disease treatment
EP1274436A1 (fr)	2003-01-15	Compositions medicales comprenant du (r,r)-formoterol et du rofleponide
US20030096874A1 (en)	2003-05-22	Respiratory compositions
KR20050094810A (ko)	2005-09-28	로플루미래스트와 ｒ,ｒ-포르모테롤을 포함하는 상승작용성조합물
US20040019025A1 (en)	2004-01-29	Medical compositions comprising (r,r)-formoterol and rofleponide
JP5220741B2 (ja)	2013-06-26	アンドラスト／グルココルチコイドの併用
JP2013056925A (ja)	2013-03-28	アンドラスト／グルココルチコイドの併用